Cancer Vaccine Targeting Brachyury Protein in Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

January 5, 2012

Primary Completion Date

March 3, 2016

Study Completion Date

September 1, 2016

Conditions
NeoplasmsMalignant Solid TumorsColon NeoplasmsAdenocarcinoma
Interventions
BIOLOGICAL

GI-6301 (Yeast Brachyury Vaccine)

GI-6301 is a heat-killed, recombinant yeast-based vaccine engineered to express the transcription factor, Brachyury. The Brachyury gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wildtype yeast) to produce the final recombinant vaccine product.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01519817 - Cancer Vaccine Targeting Brachyury Protein in Tumors | Biotech Hunter | Biotech Hunter